Minoryx Therapeutics begins its Leriglitazone phase-2 clinical trial

· A patient participating in the clinical trial has already been dosed with the company’s lead candidate, leriglitazone.

· The patient was given the dose at Hospital La Paz in Madrid by a clinical team led by Dr. Francisco Javier Rodríguez de Rivera.

Minoryx Therapeutics (Minoryx), a renowned Barcelona-based clinical stage biotech firm, has reportedly announced that it has began the dosing process for its lead drug candidate, leriglitazone (MIN-102) under the FRAMES phase-2 clinical trial.

Reports cite, the drug candidate has been developed for the treatment of Friedreich’s Ataxia (FA); a recessive genetic disease that impairs speech and use of appendages. Reportedly, a patient participating in the clinical trial has already been dosed with the drug candidate.

According to a press release by Minoryx Therapeutics, the FRAMES trial is a placebo-controlled, double-blind clinical trial that aims to assess the efficacy as well as safety of the drug candidate in patients suffering from FA.

The patient was given the dose at Hospital La Paz in Madrid by a clinical team led by Dr. Francisco Javier Rodríguez de Rivera. Apart from Madrid, following four additional sites are also conducting the FRAMES trial; Sant Joan de Déu Hospital in Barcelona, Spain led by Dr. Alexandra Darling, ICM in Paris, France led by Prof. Alexandra Durr, Hôpital Erasme-ULB in Brussels, Belgium led by Prof. Massimo Pandolfo and Universitätsklinikum RWTH in Aachen, Germany led by Prof. Jörg Schulz.

The CEO of Minoryx Therapeutics, Marc Martinell stated that the company is pleased that the FRAMES trial enrollment has started as the preclinical studies showed that there was strong rationale for developing the drug in this particular indication. Martinell further added that the company is now exploring several additional conditions that affect the central nervous system to assess whether leriglitazone might facilitate a potential benefit to patients.

According to reports, the current FRAMES Phase-2 trial would be enrolling a total of 36 patients with target ages of 12 years or above over a one-year treatment duration.

Source Credit: http://www.minoryx.com/minoryx_announces_first_patient_dosed_in_the_frames_phase_2_trial_in_friedreichs_ataxia/